Velz Julia, Freudenmann Lena K, Medici Gioele, Dubbelaar Marissa, Mohme Malte, Ghasemi David R, Scheid Jonas, Kowalewski Daniel J, Patterson Angelica B, Zeitlberger Anna M, Lamszus Katrin, Westphal Manfred, Eyrich Matthias, Messing-Jünger Martina, Röhrig Andreas, Reinhard Harald, Beccaria Kévin, Craveiro Rogeiro B, Frey Beat M, Sill Martin, Nahnsen Sven, Gauder Marie, Kapolou Konstantina, Silginer Manuela, Weiss Tobias, Wirsching Hans-Georg, Roth Patrick, Grotzer Michael, Krayenbühl Niklaus, Bozinov Oliver, Regli Luca, Rammensee Hans-Georg, Rushing Elisabeth J, Sahm Felix, Walz Juliane S, Weller Michael, Neidert Marian C
Laboratory of Molecular Neuro-Oncology, Department of Neurology, Clinical Neuroscience Center, University Hospital and University of Zurich, Zurich, Switzerland.
Department of Neurosurgery, Clinical Neuroscience Center, University Hospital and University of Zurich, Zurich, Switzerland.
Nat Commun. 2025 Feb 4;16(1):1364. doi: 10.1038/s41467-025-56268-0.
Medulloblastoma is the most frequent malignant primary brain tumor in children. Despite recent advances in integrated genomics, the prognosis in children with high-risk medulloblastoma remains devastating, and new tumor-specific therapeutic approaches are needed. Here, we present an atlas of naturally presented T cell antigens in medulloblastoma. We map the human leukocyte antigen (HLA)-presented peptidomes of 28 tumors and perform comparative immunopeptidome profiling against an in-house benign database. Medulloblastoma is shown to be a rich source of tumor-associated antigens, naturally presented on HLA class I and II molecules. Remarkably, most tumor-associated peptides and proteins are subgroup-specific, whereas shared presentation among all subgroups of medulloblastoma (WNT, SHH, Group 3 and Group 4) is rare. Functional testing of top-ranking novel candidate antigens demonstrates the induction of peptide-specific T cell responses, supporting their potential for T cell immunotherapy. This study is an in-depth mapping of naturally presented T cell antigens in medulloblastoma. Integration of immunopeptidomics, transcriptomics, and epigenetic data leads to the identification of a large set of actionable targets that can be further used for the translation into the clinical setting by facilitating the informed design of immunotherapeutic approaches to children with medulloblastoma.
髓母细胞瘤是儿童中最常见的原发性恶性脑肿瘤。尽管在综合基因组学方面取得了最新进展,但高危髓母细胞瘤患儿的预后仍然很差,因此需要新的肿瘤特异性治疗方法。在此,我们展示了髓母细胞瘤中自然呈现的T细胞抗原图谱。我们绘制了28个肿瘤的人类白细胞抗原(HLA)呈递的肽组图谱,并针对一个内部良性数据库进行了比较免疫肽组分析。结果表明,髓母细胞瘤是肿瘤相关抗原的丰富来源,这些抗原自然呈现在HLA I类和II类分子上。值得注意的是,大多数肿瘤相关肽和蛋白质是亚组特异性的,而在髓母细胞瘤的所有亚组(WNT、SHH、3组和4组)中共同呈现的情况很少见。对排名靠前的新型候选抗原进行功能测试,证明了肽特异性T细胞反应的诱导,支持了它们在T细胞免疫治疗中的潜力。这项研究是对髓母细胞瘤中自然呈现的T细胞抗原的深入图谱绘制。免疫肽组学、转录组学和表观遗传数据的整合导致鉴定出大量可操作的靶点,这些靶点可通过促进针对髓母细胞瘤患儿的免疫治疗方法的明智设计,进一步用于转化为临床应用。